Patent intelligence · US
US 11898165
Engineered host cells and methods of use thereof
Engineered host cells and methods of use thereof
Patent details — US 11898165
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 13, 2024
- Expiration
- Feb 8, 2044
- Applicant
- MiNK Therapeutics, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K35/17, A61K38/00
Quick answer
US 11898165 (Engineered host cells and methods of use thereof) is held by MiNK Therapeutics, Inc.. Status: granted. Granted Feb 13, 2024. Expires Feb 8, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MiNK Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K35/17, A61K38/00
More from MiNK Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419955
Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus
granted -
US 12391741
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
granted -
US 11718658
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
granted -
US 11613764
T cell receptors that bind to NY-ESO-1 and methods of use thereof
granted -
US 9943496
Dietary supplement based on ethyl ferulate
granted
Frequently asked questions
What is US patent 11898165?
US 11898165 (Engineered host cells and methods of use thereof) is held by MiNK Therapeutics, Inc.. Status: granted. Granted Feb 13, 2024. Expires Feb 8, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11898165?
MiNK Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11898165 expire?
Our index shows an expiration date of Feb 8, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.